Items where authors include "Pandha, HS"

Article

Rudin, CM, Pandha, HS, Zibelman, M et al. (18 more authors) (2023) Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 11 (1). e005007. ISSN 2051-1426

Roulstone, V, Khan, K, Pandha, HS et al. (8 more authors) (2015) Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clinical Cancer Research, 21 (6). 1305 - 1312. ISSN 1078-0432

Kyula, JN, Khan, AA, Mansfield, D et al. (16 more authors) (2013) Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/E BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, 33 (13). 1700 - 1712. ISSN 0950-9232

Twigger, K, Roulstone, V, Kyula, J et al. (14 more authors) (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 12. 368. ISSN 1471-2407

Simpson, GR, Horvath, A, Annels, NE et al. (10 more authors) (2012) Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British Journal of Cancer, 106. pp. 496-507. ISSN 0007-0920

Heinemann, L, Simpson, GR, Boxall, A et al. (8 more authors) (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 11 (1). ARTN 221. ISSN 1471-2407

Prestwich, RJD, Errington-Mais, F orcid.org/0000-0003-2155-534X, Harrington, KJ et al. (3 more authors) (2008) Oncolytic viruses: do they have a role in anti-cancer therapy? Clinical Medicine: Oncology, 2. pp. 83-96. ISSN 1177-9314